Anti-thymocyte globulin (ATG), raised in rabbits, is frequently used in allogeneic hematopoietic SCT (HSCT), to prevent graft rejection and acute GVHD. In solid organ transplant patients, antibodies to rabbit IgG result in an enhanced clearance of ATG. The occurrence of such antibodies in HSCT recipients and their clinical impact is unknown. Concentrations of ATG and anti-ATG antibodies were measured in 72 pediatric HSCT recipients treated with ATG as part of the conditioning. Anti-ATG antibodies were detected in 20 children (28%), all transplanted with a non-depleted graft. IgG anti-ATG, alone or combined with IgM and/or IgA anti-ATG, appeared in 10 children. Four patients developed IgG anti-ATG antibodies early (before day 22) post-HSCT. They had steep drops in ATG levels and showed rapid T-cell recovery, which was associated with a significantly increased risk of acute GVHD. In six patients IgG anti-ATG responses occurred later (range 28-46 days) after HSCT without an increased risk of GVHD. A total of 10 children only mounted an IgM (and IgA) anti-ATG response, which was without major impact on ATG levels. These results indicate that early development of IgG anti-ATG antibodies has a major impact on acute GVHD. Routine analysis ATG/anti-ATG Ab measurement should be considered.
Introduction
Polyclonal antibodies raised in horse or rabbit against thymocytes (anti-thymocyte globulin (ATG)) or activated T-cell leukemia (Jurkat cell line) or in horse against lymphocytes (anti-lymphocyte globulin (ALG)) are applied in vivo to prevent or eliminate undesired T-cell-mediated immune reactivity. The clinical settings in which ATG/ALG is used encompass solid organ transplant to prevent or treat acute graft rejection, 1, 2 allogeneic hematopoietic SCT (HSCT) to prevent graft rejection and acute GVHD, [3] [4] [5] and severe aplastic anemia to treat T-cell-mediated BM failure. 6 Sensitisation toward ATG/ALG, defined as production of anti-ATG antibodies, has been described in immunocompetent patients such as solid organ recipients and severe aplastic anemia patients. [7] [8] [9] Clearance of total ATG (rabbit or horse IgG) and active ATG (IgG capable of Ag-specific binding to cells) is more rapid in kidney transplant patients developing anti-rabbit or anti-horse antibodies. [10] [11] [12] In the HSCT setting, only one study has reported a few cases in which anti-ATG antibodies appeared shortly after transplantation, without signifying a potential clinical effect. 13 Reports on the pharmacokinetics and pharmacodynamics of ATG/ALG in adult [14] [15] [16] [17] and pediatric 18, 19 allogeneic HSCT recipients revealed a high variability between individuals. The actual peak concentration of (active) ATG/ALG achieved in a patient, together with the clearance rate in an individual, may have an impact on the clinical course after HSCT. Dosing, 3, 4, 13, 14, 16, [18] [19] [20] timing of infusion 21, 22 and the brand of ATG/ALG 23, 24 may affect immune cell depletion and the pace of immune reconstitution. Consequently, the susceptibility to viral infections, the incidence of leukemia relapse and the occurrence of graft rejection and acute GVHD might be influenced.
In this study, the pharmacokinetics of total and active rabbit ATG has been investigated in relation to clinical outcome in a large cohort of pediatric HSCT recipients. Rapid clearance of ATG was associated with appearance of an IgG anti-ATG Ab response. Enhanced Ab-mediated clearance of ATG early after HSCT had serious consequences on transplant-related toxicity.
Design and methods

Patients
The study cohort consists of 72 children, who received an allogeneic stem cell graft between 2004 and 2008 in the pediatric transplant unit of the Leiden University Medical Center. All patients, in whom serotherapy with rabbit ATG (thymoglobulin, Genzyme Europe, Naarden, The Netherlands) was part of the conditioning regimen, were included.
Patients' characteristics are listed in Table 1 . Patients were enrolled after obtaining written informed consent. Institutional ethics committee approval was obtained for the research protocol.
None of the patients had received any ATG treatment before the HSCT conditioning regimen.
Conditioning regimen and supportive care
Transplant procedures and conditioning regimens are according to the European Group for Blood and Marrow Transplantation procedures holding for the various original diseases. The total dose of ATG was 10 mg/kg given before HSCT over 3-5 days, mostly starting at day À5. All patients received anti-histamines and steroids (2 mg/kg/ day) starting 24 h before ATG infusion. GVHD prophylaxis consisted of CsA; MTX (10 mg/m 2 at day þ 1, þ 3 and þ 6) was added to the recipients of non-T-cell-depleted grafts. Standard care consisted of strict protective isolation and oral administration of antimicrobial drugs for gut decontamination. Trimethoprim-sulfamethoxazole was given as pneumocystis prophylaxis. I.v. Igs (150 mg/kg, once a week) were given to all recipients of a non-HLA-identical transplant, or guided by IgG serum concentrations. 26 was used. HUT 78 T-cells (50 000 in 50 mL; HPACC, Porton Down, UK) were incubated with 50 mL of standard and of fourfold dilutions of patients' sera. After washing, the cells were incubated with 50 mL goat anti-rabbit IgG (1:50 diluted; Biosource, Invitrogen Corporation, Carlsbad, CA, USA), washed once, followed by incubation with Alexa 488-labeled donkey anti-goat IgG Ab (1:100 diluted; Biosource; Invitrogen). All incubations were performed for 30 min on ice and in the dark. For the standard reference curve, rabbit ATG (5 mg/mL, thymoglobulin, Genzyme) was arbitrarily set at 5000 AU/mL active ATG. Thymoglobulin was diluted by making twofold dilutions in triplicate, establishing a final range from 0.005 to 5 AU/mL. Finally, the cells were washed and flow cytometry analysis was performed immediately thereafter on a FACS Scan (Becton Dickinson, Oxford, UK). Data were processed using Cell Quest software (BD Biosciences, San Jose, CA, USA).
The mean fluorescence intensities of the standard dilutions were plotted against the active ATG concentrations. With the program Softmax Pro (Molecular Devices, Sunny Valley, CA, USA), the curve of best fit was constructed using the four parameter logistic equation and used to calculate the concentration of free active ATG in sera of patients.
Total ATG (rabbit IgG) and antibodies to ATG were measured with an ELISA. For total ATG, plates were coated with goat anti-rabbit IgG adsorbed for human IgG (1:750 diluted; Jackson Europe, Suffolk, UK). After blocking and washing, standard (thymoglobulin, range 4-250 ng/mL) and diluted patients' sera (start 1:90, threefold dilutions) were incubated for 60 min at 37 1C, followed by incubation with alkaline phosphatase-conjugated goat anti-rabbit IgG adsorbed for human IgG (1:2000 diluted; Jackson Europe).
To detect anti-ATG antibodies plates were coated with 10 mg/mL ATG (thymoglobulin), and after blocking, sera were applied in four threefold dilutions (starting at 1:60). Bound human antibodies against ATG were detected with alkaline phosphatase-conjugated rabbit anti-human IgG (1:1500 diluted; Jackson Europe), goat anti-human IgM (1:1000 diluted; Biosource Invitrogen) or goat anti-human IgA (1:1000 diluted; Biosource Invitrogen). These Biosource antisera were adsorbed for rabbit IgG and showed no or minimal cross-reactivity with the coated ATG.
Because there is no reference material available for antibodies against ATG, sera with high concentration of antibodies in all isotypes were used as internal standard and control. The internal standard was defined as containing 100 AU/mL of IgM anti-ATG, IgG anti-ATG and IgA anti-ATG each and sera were considered positive if the concentration of anti-ATG antibodies was above 10% of the reference standard for the particular isotype.
Measurements of total and active ATG were performed in serum samples obtained pre-HSCT and at least once a week until week 4, and once every 2 weeks until week 13 post-HSCT. Additional sera pre-and 15 min post-ATG infusion were collected from all patients transplanted after July 2005.
All patients were screened for the presence of anti-ATG antibodies at week 4 and 8 after HSCT and before starting the ATG infusion. Patients with anti-ATG antibodies were analyzed on additional time points.
The allotypes of IgG1 of patient and donor were analyzed in pre-transplant sera with a dot immuno binding assay. 27 In couples with informative G1m allotype differences, G1m(a) and G1m(f) allotypes of IgG1 anti-ATG antbodies were quantified as described above. Allotypespecific monoclonal antibodies, HP6184 for G1m(a) (dilution 1:10 000) and HP6185 for G1m(f) (dilution 1:30 000) (kindly provided by Sanquin, Amsterdam, The Netherlands) were used, followed by incubation with alkaline phosphatase-conjugated rabbit anti-mouse IgG (dilution 1:750, Dako, Glostrup, Denmark).
Immunological reconstitution
Leukocyte and lymphocyte counts were determined every 1-3 days during the first 2 months after HSCT. Subset analysis of PBMCs (that is,
þ natural killer cells and CD19 þ CD20 þ B cells) was performed every week, when sufficient lymphocytes were present (usually from 2-3 weeks after HSCT onward), by flow cytometry.
Engraftment was defined as the day the neutrophils reached 0.5 Â 10 9 /L.
Statistics
Statistical analyses were performed using SPSS16 (IBM SPSS Inc., Chicago, IL, USA) and Prism Graphpad 5.04 (Graphpad Software, La Jolla, CA, USA). Data for different subgroups of patients were compared using the independent Student's t-test and w 2 test. Differences in the immune reconstitution between the groups were analyzed using the t-test on log-transformed data, differences in ATG concentrations were analyzed with the Mann-Whitney U-test. P-values o0.05 were considered significant. The significance of the cumulative incidence plots was calculated with a log-rank test.
Results
Serum concentration of total and active ATG During serotherapy, the serum concentrations of total and active ATG increased with each subsequent dose and reached the highest levels after the last dose usually given at day À2. Data obtained in the sera of 25 frequently sampled patients of the HSCT cohort were used to construct the median and P5 and P95 range of serum ATG levels ( Figure 1, gray lines) . Although all patients received a total dose of 10 mg ATG per kg, the variation in concentration of total and active ATG was high; that is, the median serum concentration 15 min after the last dose was 80 mg/mL (ranging from 54 to 125 mg/mL) for total ATG, and 12 AU/ mL (ranging from 5 to 25 AU/mL) for active ATG. After the final dose, the concentration of ATG decreased with a median t 1/2 of 19 days for total ATG and of 7 days for active ATG. Three months post-HSCT the median level of total ATG was 2.9 mg/mL (range 0.1-15.0 mg/mL).
Anti-ATG
In some patients total ATG levels decreased much faster than expected; that is, more than a 2-log decrease in a time span of 4 days (Figure 1 ). This observation suggested the development of an anti-ATG Ab response in these patients. Therefore, all patients (n ¼ 72) were cross-sectionally investigated for the presence of IgG, IgM and IgA antibodies directed against ATG pre-ATG therapy, and at 4 and 8 weeks post-HSCT. All patients with anti-ATG antibodies, irrespective of the isotype(s), were studied longitudinally.
In none of the HSCT recipients were anti-ATG antibodies detectable in pre-ATG therapy sera, but 28% of the patients (20 out of 72) developed anti-ATG antibodies post-HSCT (Table 1) . A total of 10 patients produced IgG anti-ATG, accompanied in most patients with IgM (9 out of 10) and IgA (9 out of 10) anti-ATG antibodies ( Table 2) .
The appearance of IgG anti-ATG antibodies was associated with a steep decrease of serum total and active ATG levels in all 10 patients as demonstrated by the data of UPN 658 and 657 (Figure 1 ). The patients who developed IgG anti-ATG antibodies post-HSCT could be divided into two groups (Table 2) anti-ATG in the absence of IgG anti-ATG did not show a steep decline of total ATG (UPN 650; Figure 1 ).
Risk factor for producing anti-ATG
Anti-ATG antibodies post-HSCT appeared only in children receiving a full graft (20 out of 59); in none of 13 patients with an 'ex vivo' CD3/CD19-depleted or CD34-enriched graft an anti-ATG Ab response occurred (Table 1 , P ¼ 0.014). Patients producing anti-ATG antibodies were older (median 9.6 vs 5.0 years, P ¼ 0.033) and had a higher body weight (median 28 vs 19 kg, P ¼ 0.05) than patients without anti-ATG antibodies. In none of the patients receiving a cord blood graft (n ¼ 12) was IgG-anti ATG detected, 3 out of 12 produced IgM anti-ATG.
Patients who received a TBI-containing regimen had a greater chance of developing anti-ATG antibodies post-HSCT compared with non-TBI-containing regimens; 60% vs 35%, respectively, (P ¼ 0.05, Table 1 ). The type of chemotherapeutic drug applied in the conditioning regimen was not significantly associated with anti-ATG development post-HSCT (data not shown).
When comparing patients, irrespective of the presence of anti-ATG, there was no correlation between the serum concentration of active/total ATG at week 1 post-HSCT and the occurrence of acute GVHD II-IV. At week 1 the geometric mean concentration of active and total ATG was the same in patients with or without GVHD; 1.95 vs 2.25 mg/mL for active ATG and 47.1 vs 44.0 mg/mL for total ATG, respectively, (both NS).
Anti-ATG Ab allotype
On the basis of the observation that anti-ATG Ab responses were observed in recipients of a full graft, together with the rapid appearance of anti-ATG antibodies after transplant, it can be hypothesized that the anti-ATG antibodies are produced by B cells of donor origin. To discern whether the antibodies were from donor or recipient origin the allotype of IgG1 anti-ATG antibodies was determined. In 7 of the 10 HSCT couples from group A and B, there was an informative G1m allotype difference between donor and recipient. Six patients exclusively had donor-type IgG1 anti-ATG and one child developed both patient-and donor-type antibodies (Table 2) .
Immune recovery
To exclude the effect of ex vivo T-cell depletion on T-cell recovery, the immune reconstitution was compared in patients receiving a full graft and mounting an anti-ATG response (n ¼ 20) with patients not developing anti-ATG (n ¼ 39). The immune recovery of T-cells was slightly but not significantly faster in patients producing anti-ATG (Figure 2 ). At 4 weeks the geometric mean of T-cells was 111 cells/mL in patients with anti-ATG vs 55 cells/mL in patients without anti-ATG (P ¼ 0.27); at 8 weeks these numbers were 351 vs 206 cells/mL (P ¼ 0.32) and at 12 weeks 396 vs 210 cells/mL (P ¼ 0.26), respectively. The recovery of natural killer and B cells was comparable in both groups (data not shown).
The T-cell recovery in patients receiving a T-cell-depleted graft without mounting anti-ATG was much slower than in patients receiving a full graft; 10, 21 and 52 cells/mL at week 4, 8 and 12 (P ¼ 0.018, 0.005 and 0.005, respectively).
Anti-ATG Ab production and GVHD The incidence of severe acute GVHD (grade II-IV) is higher in patients producing anti-ATG (35 vs 10%, P ¼ 0.01, Table 1 ). Anti-ATG production was not observed after transplantation with a T-cell-depleted graft, possibly because T-cell recovery was significantly slower in these patients (data not shown). The cumulative incidence of acute GVHD was compared in patients receiving a full graft and mounting an anti-ATG response (n ¼ 20) with patients receiving a full graft and not developing anti-ATG (n ¼ 39). The cumulative incidence of acute GVHD (grade II-IV) was significantly higher in patients producing anti-ATG than in patients without anti-ATG antibodies (P ¼ 0.019, Figure 3a) . In group A patients (n ¼ 4), with a steep drop in active and total ATG within the first 3 weeks post-HSCT, the cumulative incidence of severe acute GVHD (grade II-IV) was significantly higher (3 out of 4) than in group B patients (1 out of 6) and in children without IgG anti-ATG antibodies (4 out of 39) (Table 3; Figure 3b ; Po0.0001).
Patients with an IgM anti-ATG response without IgG anti-ATG, irrespective of the timing of the response, did not show an increased cumulative incidence of acute GVHD to the same extent as group A patients (Table 3) .
Although the incidence of acute GVHD was significantly higher in patients who produce IgG anti-ATG early post-HSCT, the overall survival of these patients at 1 year after HSCT was comparable with patients without anti-ATG (Table 3 ; Figure 3c ).
Group A patients engrafted significantly faster (n ¼ 4; mean day þ 19; range 16-21) than group B patients (n ¼ 6; mean day þ 27; range 17-33; P ¼ 0.05) or patients without anti-ATG (n ¼ 39; mean day þ 24, range 15-35; P ¼ 0.04) ( Table 3) .
A total of only 5 patients developed chronic GVHD: 3 of 20 patients (15%) in the anti-ATG group vs 2 of 52 patients (4%) in the patient group without anti-ATG (Table 1) ; this was not a significant difference (P ¼ 0.095).
Discussion
Conditioning regimens containing ATG are advised in various guidelines from the international transplantation societies. Blood levels of total and/or active ATG are, however, not measured on a regular basis in allogeneic HSCT recipients. The appearance of anti-ATG antibodies and its impact on ATG levels and clinical outcome have merely been studied in solid organ transplant recipients. 8, 9, 12, 28, 29 Presence of anti-ATG levels after HSCT has only been reported by Schleuning et al., 13 who described such antibodies in 4 of 97 adult CML patients after unrelated donor HSCT, but did not refer to the biological and clinical relevance. We detected anti-ATG antibodies from day 16 after HSCT onward, in 20 of 72 children (28%) receiving ATG before HSCT as part of the conditioning regimen. In patients with an informative allotypic IgG marker, we demonstrated that this response is of donor origin. An IgG anti-ATG response was always associated with rapid clearance of active and total ATG. When the response occurred within the first 3 weeks after HSCT, it was accompanied by an increased risk of severe acute GVHD.
The importance of ATG in the conditioning to prevent graft rejection and GVHD has been stressed in various studies. 3, 3, 5, 23, 24, 30, 31 Serotherapy to deplete donor T-cells from the stem cell graft, referred to as in vivo T-cell depletion, is usually combined with additional immunosuppressive therapy post-HSCT. 23 However, to date only limited data are available on the pharmacokinetics of ATG in adult and pediatric HSCT recipients. Consequently, dosing schedules of ATG have been developed empirically in the absence of detailed pharmacokinetics studies. 5, 14, 18 The effect of patient-and HSCT-related variables on the ATG peak levels or on the time to reach sub-therapeutic levels of active ATG in relation to outcome parameters are largely unknown. Prolonged elevated levels of active ATG may lead to delayed immune recovery of donor-derived Tcells and increased susceptibility to infections, 4, 13, 18, 23, 24 whereas very low ATG levels will increase the risk of graft rejection or GVHD, 4, 13, 23, 24, 32 as illustrated in this study in patients with rapid clearance of ATG due to early production of IgG anti-ATG antibodies.
In this study, anti-ATG Ab responses of donor origin were observed early after HSCT in the absence of any measurable peripheral blood leukocyte recovery. Restoration of immunity after HSCT is generally a slow process. The contribution of newly generated B-and T-cells of donor origin during the first weeks after transplantation may be negligible. Therefore, the initial response against the xenoprotein ATG has likely been derived from the mature donor lymphocytes co-infused with the graft. This hypothesis is supported by our observation that anti-ATG Ab responses in this cohort are exclusively present in recipients of an undepleted BM or PBSC graft and absent in recipients of a depleted graft. Indeed, in the transplant setting using a full graft, Ag-specific immunity can be adoptively transferred from donor to recipient. [32] [33] [34] The anti-ATG antibodies in serum were detectable until at least 6 months post-HSCT, and can be a risk for patients receiving a second HSCT with ATG conditioning. In patients with circulating anti-ATG at the time of a second transplant, alemtuzumab can be an alternative mode for T-cell depletion. Anti-ATG antibodies can also be found in severe aplastic anemia patients, who were treated with ATG as first line immunosuppressive therapy before HSCT and in hemophagocytic lymphohistiocytosis patients receiving upfront treatment with ATG to reduce the inflammatory state. We demonstrated that patients with a history of ATG and anti-ATG antibodies pre-HSCT conditioning, have an increased risk of rapid clearing of ATG, even pre-HSCT (Jol-van der Zijde, unpublished data).
In conclusion, measurement of total and active ATG levels and insight in the development of anti-ATG antibodies may have major implications for future transplantation policies. Detailed analyses in a larger patient cohort are needed to fully appreciate the relationship between ATG levels and immune reconstitution, GVHD and other clinical outcome parameters such as graft rejection, infections, chimerism, relapse rate, day-100 mortality and event-free survival.
With the knowledge of today, it is strongly recommended to test for anti-ATG antibodies in ATG-pre-treated patients (severe aplastic anemia or second transplants) and, if positive, to switch to alternative anti-T-cell therapy, that is, alemtuzumab, for their conditioning. Furthermore, screening for ATG levels and presence of anti-ATG antibodies in patients with early signs of immunopathology, such as severe acute GVHD, could urge for the use of additional anti-T-cell therapy. Also, skin rashes or other signs of serum sickness due to ATG-anti-ATG reactions will be better understood. Table 3 Clinical complications and outcome in patients receiving a full graft (n ¼ 59) Abbreviations: ATG ¼ anti-thymocyte globulin; CB ¼ cord blood; day of engraftment, median and range.
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